- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2426-0266
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Future of Anti-Amyloid Trials ; volume:7 ; number:3 ; day:17 ; month:4 ; year:2020 ; pages:146-151 ; date:6.2020
The journal of prevention of Alzheimer's disease ; 7, Heft 3 (17.4.2020), 146-151, 6.2020
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Aisen, P. S.
Cummings, J.
Doody, R.
Kramer, L.
Salloway, S.
Selkoe, D. J.
Sims, J.
Sperling, R. A.
Vellas, B.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.14283/jpad.2020.24
- URN
-
urn:nbn:de:101:1-2020080222512588337359
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Aisen, P. S.
- Cummings, J.
- Doody, R.
- Kramer, L.
- Salloway, S.
- Selkoe, D. J.
- Sims, J.
- Sperling, R. A.
- Vellas, B.
- SpringerLink (Online service)
Ähnliche Objekte (12)
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report
The biochemical aftermath of anti-amyloid immunotherapy
A manifesto for the future of ICU trials
Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials
Getting personal: the future of medicine and clinical trials
Lupus clinical trials and the promise of future therapies
The future of clinical trials—goals, ideas, and discussion
The amyloid precursor protein: beyond amyloid
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials
Importance of the TIMI frame count: implications for future trials
Nonsteroidal Anti-Inflammatory Drugs and Ectodomain Shedding of the Amyloid Precursor Protein
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report
The biochemical aftermath of anti-amyloid immunotherapy
A manifesto for the future of ICU trials
Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials
Getting personal: the future of medicine and clinical trials
Lupus clinical trials and the promise of future therapies
The future of clinical trials—goals, ideas, and discussion
The amyloid precursor protein: beyond amyloid
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials
Importance of the TIMI frame count: implications for future trials
Nonsteroidal Anti-Inflammatory Drugs and Ectodomain Shedding of the Amyloid Precursor Protein
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report
The biochemical aftermath of anti-amyloid immunotherapy
A manifesto for the future of ICU trials
Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials
Getting personal: the future of medicine and clinical trials
Lupus clinical trials and the promise of future therapies
The future of clinical trials—goals, ideas, and discussion
The amyloid precursor protein: beyond amyloid
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials
Importance of the TIMI frame count: implications for future trials
Nonsteroidal Anti-Inflammatory Drugs and Ectodomain Shedding of the Amyloid Precursor Protein